

Supplemental Table for:
Prognostic Factors of Survival in a Randomized Phase 3 Trial (MPACT) of Weekly nab-Paclitaxel Plus Gemcitabine vs Gemcitabine Alone in Patients With Metastatic Pancreatic Cancer
Josep Taberero et al.

Table S1. Selected baseline characteristics.

Variable		<i>nab</i> -P + Gem (<i>n</i> = 431)	Gem (<i>n</i> = 430)	All Patients (<i>N</i> = 861)
Age	Median years (min, max)	62 (27, 86)	63 (32, 88)	63 (27, 88)
	≥ 65 years, <i>n</i> (%)	177 (41)	188 (44)	365 (42)
Sex, <i>n</i> (%)	Male	245 (57)	257 (60)	502 (58)
Region, <i>n</i> (%)	North America	268 (62)	271 (63)	539 (63)
	Australia	61 (14)	59 (14)	120 (14)
	Eastern Europe	64 (15)	62 (14)	126 (15)
	Western Europe	38 (9)	38 (9)	76 (9)
KPS score, <i>n</i> (%)	70	30 (7)	33 (8)	63 (7)
	80	149 (35)	128 (30)	277 (32)
	90	179 (42)	199 (46)	378 (44)
	100	69 (16)	69 (16)	138 (16)
	70–80	179 (42)	161 (38)	340 (40)
	90–100	248 (58)	268 (62)	516 (60)
Pancreatic primary tumor location, <i>n</i> (%)	Head	191 (44)	180 (42)	371 (43)
	Body	132 (31)	136 (32)	268 (31)
	Tail	105 (24)	110 (26)	215 (25)
Number of metastatic sites, <i>n</i> (%)	1	33 (8)	21 (5)	54 (6)
	2	202 (47)	206 (48)	408 (47)
	≥ 3	196 (45)	203 (47)	399 (46)
CA19-9, <i>n</i> (%)	Normal	60 (14)	56 (13)	116 (13)
	> ULN but < 59 × ULN	122 (28)	120 (28)	242 (28)
	≥ 59 × ULN	197 (46)	195 (45)	392 (46)

CA19-9, carbohydrate antigen 19-9; Gem, gemcitabine; KPS, Karnofsky performance status; min, minimum; max, maximum; *nab*-P, *nab*-paclitaxel; ULN, upper limit of normal.